Ling Gao

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila et al. · The Lancet Oncology · 2019 · 275 citations · Full text

Medicine, Oncology, Pharmacology +16

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh et al. · Annals of Oncology · 2016 · 144 citations · Full text

Medicine, Clinical Sciences, Oncology +13

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

Daniel P. Petrylak, Scott T. Tagawa, Manish Kohli et al. · Journal of Clinical Oncology · 2016 · 84 citations

Medicine, Oncology, Pharmacotherapy +17

Differential expression of putative transbilayer amphipath transporters

Margaret S. Halleck, Joseph F. Lawler, Seth Blackshaw et al. · Physiological Genomics · 1999 · 82 citations

Life Sciences, Molecular Biology, Physiology +12

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

E. Gabriela Chiorean, Herbert I. Hurwitz, Roger B. Cohen et al. · Annals of Oncology · 2015 · 80 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +17